REPLIGEN CORP Accounts Receivable, Allowance for Credit Loss
REPLIGEN CORP (RGEN) had Accounts Receivable, Allowance for Credit Loss of $1.83 million as of 2024-12-31, per its 10-K filed 2025-03-14.
Financial Statements › Balance Sheet › Assets
us-gaap:AllowanceForDoubtfulAccountsReceivable · last filed 2025-03-14
- 2024-12-31: Accounts Receivable, Allowance for Credit Loss $1.83M.
- 2023-12-31: Accounts Receivable, Allowance for Credit Loss $2.12M.
- 2022-12-31: Accounts Receivable, Allowance for Credit Loss $1.36M.
- 2021-12-31: Accounts Receivable, Allowance for Credit Loss $1.42M.
| Period end | Accounts Receivable, Allowance for Credit Loss |
|---|---|
| 2024-12-31 | $1.83M 10-K · filed 2025-03-14 |
| 2023-12-31 | $2.12M 10-K · filed 2025-03-14 |
| 2022-12-31 | $1.36M 10-K · filed 2025-03-14 |
| 2021-12-31 | $1.42M 10-K/A · filed 2024-11-18 |
| 2020-12-31 | $762.00K 10-K · filed 2023-02-22 |
| 2020-09-30 | $621.00K 10-K · filed 2021-02-24 |
| 2020-06-30 | $538.00K 10-K · filed 2021-02-24 |
| 2020-03-31 | $658.00K 10-K · filed 2021-02-24 |
| 2019-12-31 | $525.00K 10-K · filed 2022-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |